Does the use of sodium zirconium cyclosilicate in dialysis patients reduce cardiovascular risk? Is this treatment appropriate?
No direct evidence for reducing cardiovascular risk with sodium zirconium cyclosilicate in dialysis patients. It effectively manages hyperkalemia, potentially offering indirect cardiovascular benefits by enabling RAASi therapy.
Authors
- Tripdatabase
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-19
- DOI
- https://doi.org/10.5281/zenodo.24372307
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00